| Item Type | Name |
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Protein Binding
|
|
Concept
|
Protein Conformation
|
|
Concept
|
Protein Processing, Post-Translational
|
|
Concept
|
Protein Kinases
|
|
Concept
|
Protein Biosynthesis
|
|
Concept
|
Protein Engineering
|
|
Concept
|
rac1 GTP-Binding Protein
|
|
Concept
|
Protein Structure, Quaternary
|
|
Concept
|
Mitogen-Activated Protein Kinases
|
|
Concept
|
Protein Structure, Tertiary
|
|
Concept
|
GTP-Binding Protein alpha Subunits, Gi-Go
|
|
Concept
|
BRCA1 Protein
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
Protein Transport
|
|
Concept
|
Protein Tyrosine Phosphatases
|
|
Concept
|
Protein Structure, Secondary
|
|
Concept
|
Protein Kinase C-delta
|
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
|
Concept
|
BRCA2 Protein
|
|
Concept
|
Protein C
|
|
Concept
|
Focal Adhesion Protein-Tyrosine Kinases
|
|
Concept
|
Protein Kinase C
|
|
Concept
|
Ubiquitin-Protein Ligases
|
|
Concept
|
Protein Interaction Domains and Motifs
|
|
Concept
|
CDC2 Protein Kinase
|
|
Concept
|
Retinoblastoma Protein
|
|
Concept
|
Protein Tyrosine Phosphatase, Non-Receptor Type 6
|
|
Concept
|
Mitogen-Activated Protein Kinase 1
|
|
Concept
|
Sequence Analysis, Protein
|
|
Concept
|
JNK Mitogen-Activated Protein Kinases
|
|
Concept
|
Crk-Associated Substrate Protein
|
|
Concept
|
Oncogene Protein v-cbl
|
|
Concept
|
Ribosomal Protein S6 Kinases, 70-kDa
|
|
Concept
|
Protein Interaction Maps
|
|
Concept
|
Retinoblastoma-Like Protein p130
|
|
Concept
|
Protein Kinase C-alpha
|
|
Concept
|
Protein Phosphatase 2
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
Protein Isoforms
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11
|
|
Concept
|
Protein Tyrosine Phosphatase, Non-Receptor Type 12
|
|
Academic Article
|
p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl.
|
|
Academic Article
|
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
|
|
Academic Article
|
Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL).
|
|
Academic Article
|
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
|
|
Academic Article
|
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
|
|
Academic Article
|
BCR/ABL induces multiple abnormalities of cytoskeletal function.
|
|
Academic Article
|
The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells.
|
|
Academic Article
|
The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors.
|
|
Academic Article
|
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells.
|
|
Academic Article
|
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
|
|
Academic Article
|
The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
|
|
Academic Article
|
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation.
|
|
Academic Article
|
Role of focal adhesion proteins in signal transduction and oncogenesis.
|
|
Academic Article
|
Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL.
|
|
Academic Article
|
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase.
|
|
Academic Article
|
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
|
|
Academic Article
|
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin.
|
|
Academic Article
|
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.
|
|
Academic Article
|
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells.
|
|
Academic Article
|
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.
|
|
Academic Article
|
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
|
|
Academic Article
|
The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo.
|
|
Academic Article
|
A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion.
|
|
Academic Article
|
Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
|
|
Academic Article
|
A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration.
|
|
Academic Article
|
Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins.
|
|
Academic Article
|
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.
|
|
Academic Article
|
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
|
|
Academic Article
|
Role of the cytoskeletal protein paxillin in oncogenesis.
|
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
|
Academic Article
|
Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases.
|
|
Academic Article
|
Role of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
|
|
Academic Article
|
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
|
|
Academic Article
|
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer.
|
|
Academic Article
|
Targeted molecules in small cell lung cancer.
|
|
Academic Article
|
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
|
|
Academic Article
|
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
|
|
Academic Article
|
Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2.
|
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
|
Academic Article
|
c-Met inhibition.
|
|
Academic Article
|
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
|
|
Academic Article
|
c-Met: structure, functions and potential for therapeutic inhibition.
|
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
|
Academic Article
|
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
|
|
Academic Article
|
Protein kinase C beta in malignant pleural mesothelioma.
|
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
|
Academic Article
|
Biology and novel therapeutics for neuroendocrine tumors of the lung.
|
|
Academic Article
|
Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1.
|
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
|
Academic Article
|
Receptor tyrosine kinases and inhibitors in lung cancer.
|
|
Academic Article
|
Role of c-Met in cancer: emphasis on lung cancer.
|
|
Academic Article
|
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
|
|
Academic Article
|
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
|
|
Academic Article
|
Fyn: a novel molecular target in cancer.
|
|
Academic Article
|
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
|
|
Academic Article
|
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.
|
|
Academic Article
|
Non-receptor tyrosine kinase inhibitors in lung cancer.
|
|
Academic Article
|
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.
|
|
Academic Article
|
Differential expression of RON in small and non-small cell lung cancers.
|
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
|
Academic Article
|
Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications.
|
|
Academic Article
|
Therapeutic targeting of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL.
|
|
Academic Article
|
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.
|
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
|
Academic Article
|
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.
|
|
Academic Article
|
Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
|
|
Academic Article
|
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
|
Academic Article
|
Tyrosine kinase mutations in human cancer.
|
|
Academic Article
|
c-Met is a potentially new therapeutic target for treatment of human melanoma.
|
|
Academic Article
|
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.
|
|
Academic Article
|
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.
|
|
Academic Article
|
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
|
|
Academic Article
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
|
Academic Article
|
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
|
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
|
Academic Article
|
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1).
|
|
Academic Article
|
Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.
|
|
Academic Article
|
Involvement of the adapter protein CRKL in integrin-mediated adhesion.
|
|
Academic Article
|
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.
|
|
Academic Article
|
Key signaling pathways and targets in lung cancer therapy.
|
|
Academic Article
|
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
|
|
Academic Article
|
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.
|
|
Academic Article
|
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
|
|
Academic Article
|
Novel targets for therapeutic agents in small cell lung cancer.
|
|
Academic Article
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
|
Academic Article
|
Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL.
|
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
|
Academic Article
|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
|
|
Academic Article
|
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
|
|
Academic Article
|
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity.
|
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
|
Academic Article
|
Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function.
|
|
Academic Article
|
Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.
|
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
|
Academic Article
|
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
|
Academic Article
|
Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.
|
|
Academic Article
|
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
|
|
Academic Article
|
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
|
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
|
Academic Article
|
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
|
|
Academic Article
|
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
|
|
Academic Article
|
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
|
|
Academic Article
|
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
|
|
Academic Article
|
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
|
|
Academic Article
|
Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin.
|
|
Academic Article
|
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
|
|
Academic Article
|
PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.
|
|
Academic Article
|
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
|
|
Academic Article
|
ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy.
|
|
Academic Article
|
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
|
|
Academic Article
|
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
|
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
|
Academic Article
|
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
|
|
Academic Article
|
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
|
|
Academic Article
|
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
|
|
Academic Article
|
FAK and paxillin, two potential targets in pancreatic cancer.
|
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
|
Academic Article
|
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
|
|
Academic Article
|
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
|
|
Academic Article
|
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
|
|
Academic Article
|
TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
|
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
|
Academic Article
|
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
|
|
Academic Article
|
Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
|
|
Academic Article
|
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
|
|
Academic Article
|
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.
|
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
|
Academic Article
|
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.
|
|
Academic Article
|
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
|
|
Academic Article
|
RLIP: An existential requirement for breast carcinogenesis.
|
|
Academic Article
|
Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level.
|
|
Academic Article
|
Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.
|
|
Academic Article
|
USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks.
|
|
Academic Article
|
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
|
|
Academic Article
|
RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis.
|
|
Academic Article
|
Presence and structure-activity relationship of intrinsically disordered regions across mucins.
|
|
Academic Article
|
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines.
|
|
Academic Article
|
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
|
|
Academic Article
|
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
|
|
Academic Article
|
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.
|
|
Academic Article
|
MET receptor in oncology: From biomarker to therapeutic target.
|
|
Academic Article
|
Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer.
|
|
Academic Article
|
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
|
|
Academic Article
|
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
|
|
Academic Article
|
Activating p53 function by targeting RLIP.
|
|
Academic Article
|
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
|
|
Academic Article
|
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin ß-Like 1-ß-Catenin Protein Complex.
|
|
Academic Article
|
The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
|
Academic Article
|
Protein conformational dynamics and phenotypic switching.
|
|
Academic Article
|
Intrinsically Disordered Proteins: Critical Components of the Wetware.
|
|
Academic Article
|
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
|
|
Academic Article
|
Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
|
Academic Article
|
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
|
|
Academic Article
|
MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.
|
|
Academic Article
|
RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling.
|
|
Concept
|
Forkhead Box Protein M1
|
|
Concept
|
Src Homology 2 Domain-Containing, Transforming Protein 1
|
|
Concept
|
Protein Domains
|
|
Concept
|
Fanconi Anemia Complementation Group N Protein
|
|
Concept
|
T-Lymphoma Invasion and Metastasis-inducing Protein 1
|
|
Concept
|
Inhibitor of Growth Protein 1
|
|
Concept
|
Protein Kinase C beta
|
|
Grant
|
Role of Paxillin in Lung Cancer
|
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|
|
Grant
|
PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN
|
|
Academic Article
|
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
|
|
Academic Article
|
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
|